|
1
|
Cai J, Zhu P, Zhang C, Li Q, Wang Z, Li G,
Wang G, Yang P, Li J, Han B, et al: Detection of ATRX and
IDH1-R132H immunohistochemistry in the progression of 211 paired
gliomas. Oncotarget. 7:16384–16395. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li QJ, Cai JQ and Liu CY: Evolving
molecular genetics of glioblastoma. Chin Med J (Engl). 129:464–471.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang
X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice
guidelines for the management of adult diffuse gliomas. Cancer
Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chamberlain MC: Temozolomide: Therapeutic
limitations in the treatment of adult high-grade gliomas. Expert
Rev Neurother. 10:1537–1544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao
G, Chen Y, Li Y and Zhao G: NVP-BEZ235, a novel dual PI3K-mTOR
inhibitor displays anti-glioma activity and reduces chemoresistance
to temozolomide in human glioma cells. Cancer Lett. 367:58–68.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: Implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang H, Lin H, Zhang X and Li J:
Resveratrol reverses temozolomide resistance by downregulation of
MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Oncol Rep. 27:2050–2056. 2012.PubMed/NCBI
|
|
11
|
Shi F, Guo H, Zhang R, Liu H, Wu L, Wu Q,
Liu J, Liu T and Zhang Q: The PI3K inhibitor GDC-0941 enhances
radiosensitization and reduces chemoresistance to temozolomide in
GBM cell lines. Neuroscience. 346:298–308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun
SH, Kim HH and Kim IA: Enhanced cytotoxic effect of radiation and
temozolomide in malignant glioma cells: Targeting PI3K-AKT-mTOR
signaling, HSP90 and histone deacetylases. BMC Cancer. 14:172014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan S, Sun Z, Jiang D, Dai C, Ma Y, Zhao
Z, Liu H, Wu Y, Cao Z and Li W: BmKCT toxin inhibits glioma
proliferation and tumor metastasis. Cancer Lett. 291:158–166. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu YJ, An N, Chan KG, Wu YB, Zheng SH and
Liang AH: A model of BmK CT in inhibiting glioma cell migration via
matrix metalloproteinase-2 from experimental and molecular dynamics
simulation study. Biotechnol Lett. 33:1309–1317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu YJ, Yin LT, Liang AH, Zhang CF, Wang W,
Chai BF, Yang JY and Fan XJ: Therapeutic potential of
chlorotoxin-like neurotoxin from the Chinese scorpion for human
gliomas. Neurosci Lett. 412:62–67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soroceanu L, Manning TJ Jr and Sontheimer
H: Modulation of glioma cell migration and invasion using Cl(−) and
K(+) ion channel blockers. J Neurosci. 19:5942–5954.
1999.PubMed/NCBI
|
|
17
|
Wang P, Ye JA, Hou CX, Zhou D and Zhan SQ:
Combination of lentivirus-mediated silencing of PPM1D and
temozolomide chemotherapy eradicates malignant glioma through cell
apoptosis and cell cycle arrest. Oncol Rep. 36:2544–2552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Batista LF, Roos WP, Kaina B and Menck CF:
p53 mutant human glioma cells are sensitive to UV-C-induced
apoptosis due to impaired cyclobutane pyrimidine dimer removal. Mol
Cancer Res. 7:237–246. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao L, Au JL and Wientjes MG: Comparison
of methods for evaluating drug-drug interaction. Front Biosci
(Elite Ed). 2:241–249. 2010.PubMed/NCBI
|
|
21
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:pp. 4240–4245. 1999; View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sarkaria JN, Kitange GJ, James CD, Plummer
R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to
alkylating agents in malignant glioma. Clin Cancer Res.
14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gallia GL, Tyler BM, Hann CL, Siu IM,
Giranda VL, Vescovi AL, Brem H and Riggins GJ: Inhibition of Akt
inhibits growth of glioblastoma and glioblastoma stem-like cells.
Mol Cancer Ther. 8:386–393. 2009. View Article : Google Scholar : PubMed/NCBI
|
